Our system for evaluating older drugs doesn't work; With Menendez indictment, pharmaceutical industry could lose a key ally

Taking stock of the drug industry, from the lab to the medicine chest

September 27, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

PATRICK T. FALLON/AFP via Getty Images STAT+ | Over-the-counter Sudafed PE doesn't work. Neither does our system for evaluating older drugs Experts say the U.S. lacks a robust system to run clinical trials of older drugs to confirm their benefits. By Matthew Herper STAT+ | With Menendez indictment, pharmaceutical industry could lose a key ally Sen. Bob Menendez (D-N.J.), who's embroiled in a financial scandal, is one of the pharmaceutical industry's top Democratic allies. By Sarah Owermohle STAT+ | The Ozempic revolution is rooted in the work of Svetlana Mojsov, yet she's been edged out of the story Svetlana Mojsov, chemist who played an important role in discovering GLP-1, a hormone vital for diabetes and obesity treatments, seeks her place in history. By Elaine Chen and Megan Molteni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser